The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of capecitabine with or without ramucirumab (IMC-1121B) or IMC-18F1 in patients with unresectable, locally advanced or metastatic breast cancer (mBC) previously treated with anthracycline and taxane therapy (CP20-0903/NCT01234402).
L. T. Vahdat
Consultant or Advisory Role - Bristol-Myers Squibb; Eisai
Honoraria - Bristol-Myers Squibb; Eisai
Research Funding - Bristol-Myers Squibb; Celldex; Eisai; ImClone Systems; Novartis
K. Miller
No relevant relationships to disclose
J. A. Sparano
No relevant relationships to disclose
H. Youssoufian
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
J. D. Schwartz
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
S. Nanda
Employment or Leadership Position - ImClone Systems
W. Wang
Employment or Leadership Position - ImClone Systems
L. Abad
Employment or Leadership Position - ImClone Systems
A. Dontabhaktuni
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
M. D. Rutstein
Employment or Leadership Position - ImClone Systems
Stock Ownership - Amgen; Lilly